Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic Disorder

Travere Therapeutics Inc TVTX reported topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase for classical homocystinuria (HCU). 

  • There were no discontinuations due to treatment-related adverse events. 
  • One serious adverse event, moderate acute urticaria (hives), was categorized to be likely related to pegtibatinase treatment but did not lead to treatment discontinuation and resolved following a single dose interruption.
  • Pegtibatinase demonstrated dose-dependent reductions in tHcy during the 12 weeks of treatment.
  • At the two highest doses, pegtibatinase appeared to reduce tHcy regardless of starting baseline tHcy levels or background therapy.
  • In the highest dose cohort to date of 1.5mg/kg BIW, pegtibatinase resulted in rapid and sustained reductions in tHcy, resulting in a maintenance of tHcy below a clinically meaningful threshold of 100 μmol from week 2 through week 12 of treatment.
  • In the 1.5mg/kg BIW dose cohort, treatment with pegtibatinase resulted in a mean relative reduction from baseline of 55.1%, compared to a decrease of 4.8% for all patients receiving placebo in the study.
  • Related Link: See Why Travere Therapeutics Stock Moving Higher On Tuesday.
  • Price Action: TVTX shares are down 4.17% at $25.25 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!